Novartis Scemblix® demonstrates sustained response rate

/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...

Related Keywords

United States , East Hanover , Pennsylvania , Philadelphia , America , American , Michaelj Mauro , Jeff Legos , Julie Masow , Sloan Simpson , Prnewswire Novartis , Floriana Riccio Furnari , Novartis Oncology Congress Hub , Twitter , Novartis Oncology Communications , Novartis Us External Communications , Novartis , Exchange Commission , Pfizer , Approval Program , Nj Novartis Pharmaceuticals Corporation , American Society Of Hematology Annual Meeting Exposition , Novartis Pharmaceuticals Corp , American Society , Hematology Annual Meeting , Myeloproliferative Neoplasms Program Leader , Memorial Sloan Kettering Cancer Center , Executive Vice President , Global Head , Hematology Development , Novartis Commitment , Prescribing Information , Pharmaceuticals Corporation , Safety Results , Chronic Myeloid Leukemia , Chronic Phase , Tyrosine Kinase Inhibitors , Randomized Study , Provides Durable Molecular Response , Primary Efficacy , Allosteric Inhibitor , Tyrosine Kinase Activity , Reveals Significant , Durable Responses , Exhibits Safety , Phasei Study , Asciminib Plus Nilotinib , Therapy Using Asciminib Plus Imatinib , Myeloid Leukemia , Previously Treated With , Adult Patients With Newly Diagnosed , More Tyrosine Kinase , Patients With , Pediatric Patients With Chronic Myeloid Leukemia , Treatment Optimization , Open Label , Once Daily , Newly Diagnosed Adult Patients , Pediatric Patients , Philadelphia Chromosome , Positive Chronic Myeloid Leukemia , Chronic Phase Treated , Tyrosine Kinase , Riccio Furnari , Oncology Communications , Novartis Us ,